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Abstract
Poor drug delivery and penetration of antibody-mediated therapies pose significant obstacles to effective treatment
of solid tumors. This study explored the role of pharmacokinetics, valency, and molecular weight in maximizing drug
delivery. Biodistribution of a fibroblast growth factor receptor 4 (FGFR4) targeting CovX-body (an FGFR4-binding
peptide covalently linked to a nontargeting IgG scaffold; 150 kDa) and enzymatically generated FGFR4 targeting
F(ab)2 (100 kDa) and Fab (50 kDa) fragments was measured. Peak tumor levels were achieved in 1 to 2 hours for
Fab and F(ab)2 versus 8 hours for IgG, and the percentage injected dose in tumors was 0.45%, 0.5%, and 2.5%,
respectively, compared to 0.3%, 2%, and 6% of their nontargeting controls. To explore the contribution of multi-
valent binding, homodimeric peptides were conjugated to the different sized scaffolds, creating FGFR4 targeting
IgG and F(ab)2 with four peptides and Fab with two peptides. Increased valency resulted in an increase in cell surface
binding of the bivalent constructs. There was an inverse relationship between valency and intratumoral drug con-
centration, consistent with targeted consumption. Immunohistochemical analysis demonstrated increased size
and increased cell binding decreased tumor penetration. The binding site barrier hypothesis suggests that limited
tumor penetration, as a result of high-affinity binding, could result in decreased efficacy. In our studies, increased
target binding translated into superior efficacy of the IgG instead, because of superior inhibition of FGFR4 prolifera-
tion pathways and dosing through the binding site barrier. Increasing valency is therefore an effective way to
increase the efficacy of antibody-based drugs.
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Introduction
Effective antibody therapies for targeting solid tumors are limited by
poor penetration [1] and very low percent of injected dose (ID)
reaching tumor [2]. Limited tumor penetration, caused by hetero-
geneous antigen expression [3] and blood supply [4], increased inter-
stitial fluid pressure [5,6], as well as a so-called “binding site barrier”
caused by high-affinity binding [7,8] are thought to contribute to less
effective therapy by leaving viable cells untargeted [6]. As a conse-
quence, alternatives to full-length IgG drugs have been widely inves-
tigated as a means of improving penetration [9,10].
Using a fibroblast growth factor receptor 4 (FGFR4) targeting
CovX-body (a nontargeting IgG, covalently linked to an FGFR4-
targeting peptide; 150 kDa) and enzymatically generated FGFR4
targeting F(ab)2 (100 kDa) and Fab (50 kDa), we addressed the role
of size, pharmacokinetics (PK), and avidity in tumor uptake, pene-
tration, and ultimately efficacy.
Net drug levels in the tumor are driven by the PK properties
(influenced by the dose and rate of plasma clearance), diffusion rate
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(determined by the size and properties of the biotherapeutic), bind-
ing affinity, and rate of consumption of the drug [3,11,12].
IgG drug scaffolds inherently have excellent PK properties compared
to other protein therapeutics because of both their molecular weight
and ability to bind to the neonatal FcRn receptor, which recycles
molecules that bind to them back to the serum maintaining elevated
levels. The limited and heterogeneous tumor penetration of IgGs,
however, has led to the use of smaller IgG fragments such as Fabs,
scFv′s, and diabodies [13–15], which can, in theory, diffuse more
efficiently through tumors, translating into more favorable ID ratios
at earlier time points [16]. The use of antibody fragments though must
be balanced by the shorter serum half-lives of non–Fc-containing con-
structs and the potential for more rapid distribution to normal tissues.
As well as PK, increased valency may also drive tumor biodistribu-
tion and efficacy, although the role of valency in tumor retention has
yielded sometimes conflicting data. Increasing the valency increased the
tumor uptake of human epidermal growth factor receptor 2 (HER2)
binding diabodies [13,17], while increasing the valency of HER2 bind-
ing DARPins, decreased tumor uptake [18]. In those studies, increased
valency was achieved by doubling the molecular weight, and therefore,
the role of increasing the size (and potentially decreasing clearance time)
in tumor uptake and retention could not be distinguished from the
role of increased valency. However, in other studies using divalent
(scFv′)2 molecules with zero, one, and two binding sites (same molec-
ular weight), three-fold greater tumor retention was achieved with the
construct with two binding sites [19].
A CovX-body is a peptide antibody fusion generated by conjugat-
ing a peptide on an azetidinone linker to a nonbinding humanized
IgG1 monoclonal aldolase antibody [20]. The CovX-body technol-
ogy allows the increase in the number of targeting peptides on our
scaffolds from two to four on the bivalent IgG and F(ab)2 and from
one to two on the Fab using homodimeric FGFR4-targeting pep-
tides. Increasing the valency of the constructs allows for the mea-
surement of the role of increased valency on tumor uptake and
penetration without significantly altering the molecular weight of
the targeting scaffolds. Increasing the valency of our constructs in-
creased cell binding of the bivalent constructs. It did not significantly
increase tumor levels and decreased the penetration of the scaffolds
into the tumor after a single dose, presenting a so-called “binding site
barrier.” The binding site barrier is the phenomenon whereby high-
affinity antibodies accumulate around the vasculature and fail to
distribute evenly throughout the tumor [8]. This dynamic barrier
can be overcome by increasing the dose of the antibody [7,21]. In a
multi-dose efficacy study comparing the tumor growth inhibition
(TGI) of the IgG homodimer peptide construct versus the IgG mono-
mer peptide, superior efficacy is observed with the homodimer IgG.
This current study demonstrates that in a single dose study, PK is
the most important driver of maximal tumor levels. While higher levels
of Fab were seen in the tumor after an hour than the IgG and F(ab)2,
superior maximal tumor concentrations are achieved with the IgG con-
structs. Increasing the avidity of an IgG is an effective way to maximize
the efficacy of our targeting scaffolds.
Materials and Methods
Generating F(ab)2 and Fab Scaffolds
CVX-2000, a humanized IgG1κ antibody [22], was digested over-
night at 37°C with immobilized papain (Thermo Scientific, Waltham,
MA) to produce Fab or immobilized pepsin (Thermo Scientific) to pro-
duce F(ab)2. Fab fragments were purified by size exclusion followed by
binding and elution to Protein L to separate Fab fragments from Fc
fragments. F(ab)2 fragments were purified by size exclusion, followed
by cation exchange. Final fractions were analyzed on a Bioanalyzer
(2100) protein electrophoresis chip (Agilent Technologies, Santa Clara,
CA; Figure W1).
CVX-2000, F(ab)2, and Fab constructs were conjugated with a
monomeric or homodimeric FGFR4-targeting peptide through an
azetidinone linker on the peptide, which reacts specifically with a lysine
in the Fab arm [23]. The original FGFR4-targeting peptide was dis-
covered by phage display and synthesized as described previously
[20]. Nontargeted controls of the scaffolds were conjugated with a
nonbinding peptide.
Direct binding ELISA. High-binding half-well 96-well plates
were coated overnight at 4°C with recombinant human FGFR4-Fc
(R&D Systems, Minneapolis, MN) or CVX-2000 anti-idiotype anti-
body for total scaffold measurements. After washing and blocking,
titrated compounds were then added to the plates and incubated
at room temperature for 1 hour, followed by incubation with goat
anti-human IgG-HRP (Jackson ImmunoResearch Laboratories, West
Grove, PA) at room temperature for 1 hour. Tetramethylbenzidine
substrate solution (KPL, Gaithersburg, MD) was added, and OD450
was measured. Half maximal effective concentration (EC50) value was
obtained from the dose-response curve from the experiment.
Competitive ELISA. High-binding half-well 96-well plates were
coated with goat anti-human IgG-Fc (Bethyl Laboratories,Montgomery,
TX) at 4°C overnight. After washing and blocking, plates were incu-
bated with recombinant human FGFR4-Fc for 1 hour at room tem-
perature. Plates were washed, and titrated compounds were added in
the presence of 50 ng/ml recombinant human FGF19 (R&D Systems)
and 1 μg/ml heparan sulfate (Seikagaku/Amsbio, Lake Forest, CA) and
incubated for 2 hours at room temperature. The bound compounds
were detected by biotinylated anti-FGF19 antibody (R&D Systems),
followed by incubation with streptavidin-HRP (Fitzgerald Industries,
Acton, MA). OD450 was measured.
Surface plasmon resonance binding analysis. Surface plasmon
resonance (SPR) binding analyses of anti-FGFR4 compounds were
performed on ProteOn XPR36 instrument (BioRad, Hercules, CA)
at 25°C. For kinetic analysis, recombinant human FGFR4-Fc protein
(R&D Systems) was immobilized on parallel surfaces of a GLM chip
(BioRad) by amine coupling according to the manufacturer’s protocol.
Running buffer was phosphate-buffered saline (PBS) with 300 mM
sodium chloride and 0.05% (vol/vol) Tween 20. FGFR4 immobili-
zation level was 990 RU for Fab binding and 640 RU for F(ab)2 and
IgG binding. Compounds were tested for binding to FGFR4 starting
at 200 nM at a flow rate of 50 μl/min. Association was monitored for
180 seconds, and dissociation was monitored for 600 seconds. Chip
was regenerated with 0.85% (vol/vol) phosphoric acid in water. Data
were double-referenced to blank chip surface and buffer injection and
fitted to 1:1 binding model with local Rmax using ProteOn Manager
software (BioRad) to determine kinetic rate constants and KD. Kinetic
constants are averaged from three independent experiments.
For evaluation of monomer and homodimer peptide–conjugated
compounds by capture of the compounds, anti-idiotype monoclonal
antibody for CVX-2000 was immobilized across all surfaces of a
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GLM chip (BioRad) to 10,000 RU. Running buffer was PBS with
0.01% (vol/vol) Tween 20; 50 nM Fab, 10 nM F(ab)2, 10 nM IgG
monomer and 80 nM Fab, 20 nM F(ab)2, 20 nM IgG homodimer-
conjugated constructs were captured with anti-idiotype CVX-2000
antibody. FGFR4-Fc (10 nM; R&D Systems) protein was tested
for binding to anti-FGFR4 compounds captured on the chip. Data
were double-referenced to chip surface and buffer blank.
Huh-7 cell line. Huh-7 cells were obtained from Japan Health
Science Research Resources Bank (Osaka, Japan; Cat. JCRB0403) and
were in Dulbecco’s modified Eagle’s medium (Invitrogen, Carlsbad,
CA) containing 10% FBS and maintained at 37°C and 5% CO2.
Flow cytometry (FACS). Huh-7 cells were harvested with cell
stripper and resuspended in FACS buffer (PBS + 10% FBS + 1%
sodium azide). Cells were incubated with FGFR4-targeting scaffolds
for 1 hour on ice. Cells were then washed and incubated with phy-
coerythrin (PE)-labeled Goat Anti-Human IgG, F(ab′)2 Fragment
Specific secondary antibody (Jackson ImmunoResearch Laboratories)
for 30 minutes. Cell binding was measured using a flow cytometer
(BD Biosciences, San Diego, CA). Data were analyzed using FloJo
software (TreeStar Inc, Ashland, OR).
PK in rodents. PK properties of constructs were assessed in 5-week-
old male Swiss Webster mice weighing 18 to 20 g (Charles River
Laboratories, Wilmington, MA). Compounds were administered
intravenously (i.v.) at 10 mg/kg (n = 3), and blood samples were
collected over a period of 5 days. Serum samples were prepared and
analyzed for FGFR4 binding activity in binding ELISAs as described
previously. Total scaffold levels were measured by binding to a CVX-
2000 anti-idiotype antibody capture ELISA. Data were analyzed using
WinNonlin software (Pharsight, St Louis, MO) to generate PK
parameter estimates.
Preparation of near-infrared–conjugated constructs. FGFR4
targeting CovX-bodies (IgG) and F(ab)2 and Fab constructs were
labeled with IRDye 800CW (LI-COR Biosciences, Lincoln, NE).
In brief, constructs were buffer exchanged into 50 mM sodium phos-
phate buffer (pH 7) and incubated with two equivalents of the dye to
the antibody solution overnight at room temperature in the dark.
Constructs were buffer exchanged several times in Amicon spin filters
[50 kDa molecular weight cut off (MWCO)] to remove free dye.
Dye-to-protein ratios were calculated according to the manufacturer’s
instructions using the A780 and A280 measurements.
In vivo xenograft studies. Xenografts were induced by subcuta-
neous implantation of Huh-7 tumor cells into 5- to 7-week-old female
nu/nu mice (18-20 g at start of experiment) and allowed to grow to a
volume of 200 to 400 mm3 before initiation of treatment. Once tumors
were established, mice were randomized to treatment groups on the
basis of their tumor volumes for all in vivo studies described below.
In vivo animal imaging. Near-infrared–conjugated compounds
were administered at 3 and 10 mg/kg by intraperitoneal (i.p.) injection
(no significant difference in tumor uptake was observed in a pilot study
comparing i.p. vs i.v. injection). Mice were anesthetized with 5% iso-
flurane for induction and maintained at 2% during image capture.
The images were acquired at the indicated time points with an IVIS
Lumina II Imaging System (PerkinElmer, Waltham, MA). A charge-
coupled device (CCD) camera was used to collect the images. The
images were analyzed using Living Image Software 4.0 (PerkinElmer).
Regions of interest were quantified for mean pixel values.
Biodistribution studies. Mice were dosed at 30 mg/kg i.p. injection,
and tumors were harvested at maximal accumulation time points
derived from imaging study (1 hour for Fab, 2 hours for F(ab)2, and
8 hours for IgG). Tumors and normal tissue were harvested for
biodistribution and histologic evaluation. For total scaffold accumula-
tion, tissues were homogenized using FastPrep Lysing Matrix D Tubes
(MP Biomedicals, Santa Ana, CA). Tissues were placed in tubes in a
cell lysis buffer (Cell Signaling Technology, Danvers, MA) containing
HALT protease and phosphatase inhibitor cocktail (Thermo Scientific).
Tubes were then pulse homogenized using a FastPrep-24 instrument
(MP Biomedicals) followed by incubation on a shaker at 4°C for an
hour. Samples were then spun at 14,000 rpm for 10 minutes, and the
supernatant was removed to a fresh tube. Samples were then applied
directly to CVX-2000 anti-idiotype capture binding ELISA plates for
total scaffold measurement.
In vivo efficacy study. Mice were randomized into groups of
10 mice per group. All compounds were administered once weekly at
30 mg/kg by i.p. injection. Tumor volumes were measured once or
twice weekly using calipers. Once the mean tumor volume of each
treatment group exceeded 2000 mm3, mice were killed by CO2
asphyxiation followed by cervical dislocation. Tumors and normal
tissue were harvested for histologic evaluation.
Immunohistochemistry
Tumors from the biodistribution study described above were fixed
in formalin for 24 hours. Tumors were embedded in paraffin blocks,
sectioned, and mounted for immunohistochemistry. After deparaffi-
nization and rehydration, heat-mediated antigen retrieval was per-
formed using antigen retrieval buffer (Abcam, Cambridge, United
Kingdom) for 30 minutes. Slides were incubated in 1% H2O2 for
10 minutes followed by a blocking step for 30 minutes and primary
antibody incubation. Blood vessels were detected using rabbit anti-
CD31 antibody (Abcam; ab28364) overnight at 4°C. Sections were
washed with PBS containing 0.01% Tween-20 and incubated with
biotin anti-rabbit antibody (Jackson ImmunoResearch Laboratories)
for 1 hour at room temperature followed by alkaline phosphatase–
conjugated streptavidin ( Jackson ImmunoResearch Laboratories)
for 1 hour. Sections were washed and incubated with Vector Red
Alkaline Phosphatase Substrate Kit (Vector Labs, Burlingame, CA)
for 20 minutes. For dual staining, sections were washed and incu-
bated in HRP-conjugated donkey anti-human IgG secondary antibody
(Jackson ImmunoResearch Laboratories) overnight at 4°C. Sections
were washed and incubated in DAB peroxidase substrate kit (Vector
Labs), dehydrated, and mounted. Images were captured using a Leica
SCN400 slide scanner (Leica Biosystems, Wetzlar, Germany) at ×40,
and images were analyzed on Leica SCN400 Image Viewer software.
Tumor penetration was quantified using Image-Pro plus software
(Media Cybernetics Inc, Rockville, MD). Five isolated vessels were
randomly selected per slide with the distance (in μm) the scaffolds
penetrated measured twice with each measurement taken on opposite
sides. Statistical significance was determined using Prism (GraphPad
Software, San Diego, CA). FGFR4 staining was measured using a rat
anti–hFGF-R4 primary antibody (R&D Systems), followed by an
HRP-goat anti-rat IgG secondary antibody (Jackson ImmunoResearch
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Laboratories) for 1 hour at room temperature. Sections were washed
and incubated using a DAB peroxidase substrate kit (Vector Labs).
Phospho-p44 Mitogen-Activated Protein Kinase (Extracellular
Signal-Regulated Protein Kinase) Assay
Phospho-extracellular signal-regulated protein kinase (Erk1/2) was
measured using a PathScan Phospho-p44 mitogen-activated protein
kinase (MAPK) Sandwich ELISA Kit (Cell Signaling Technology;
Cat. No. 7315). Homogenized tumor lysates from our biodistribu-
tion study were used according to the manufacturer’s instructions. In
brief, 100 μl was placed in microwells and incubated for 2 hours at
37°C. Wells were then washed four times with provided wash buffer
and incubated with detection antibody for 1 hour at 37°C. Wells were
washed and incubated in HRP-conjugated secondary antibody for
30 minutes at 37°C. Wells were washed and incubated with tetra-
methylbenzidine substrate for 10 minutes at 37°C, STOP solution
was added, and OD450 was measured.
Internalization Studies
All scaffolds were biotinylated using EZ-Link Sulfo-NHS-LC-
Biotin (Thermo Scientific) according to the manufacturer’s instruc-
tions. Huh-7 cells were harvested using Cellstripper (Cellgro,Manassas,
VA) and seeded at 100,000 cells per well in PBS4 (1 mMMgCl, 1 mM
CaCl2, 0.2% BSA, 5 mM glucose, and 10% FBS). Compounds
were added and cell incubated at 37°C for 0, 15, 30, 60, and 120 min-
utes. Plates were placed on ice for 5 minutes to stop internalization
and washed three times in PBS4. Cells were then incubated in Avidin
(Sigma, St Louis, MO; at 100 μg/ml) at 4°C for 1 hour. Biocytin
(Sigma; 1 mg/ml) was then added for 10 minutes. Cells were cen-
trifuged, the supernatant was discarded, and cells were solubilized for
30 minutes at 4°C. Total amount of internalized scaffold was measured
in supernatant by CVX-2000 anti-idiotype capture binding ELISA
followed by incubation with streptavidin-HRP (Fitzgerald Industries).
Statistical Analyses
Data were analyzed either by two-way analysis of variance (ANOVA)
with a Bonferroni post-test or by a two-tailed t test using Prism (Graph-
Pad Software).
Results
In Vitro Characterization of Scaffolds
CVX-2000, F(ab)2, and Fab constructs were conjugated with
monomer FGFR4-targeting peptide as described in the Materials
and Methods section.
Binding to FGFR4 was measured by ELISA and SPR. The IgG
and F(ab)2 constructs bind with an apparent binding affinity of
Figure 1. Characterization of FGFR4 binding scaffolds. (A) IgG, F(ab)2, and Fab constructs bind specifically to FGFR4. (B) In an FGF19
competition ELISA, all constructs compete with FGF19 to bind to FGFR4. (C) All constructs bind to Huh-7 cells. (D) PK curves of IgG, F(ab)2,
and Fab following a single i.v. dose of 10 mg/kg in Swiss Webster mice. Both total and FGFR4 binding were measured as described in the
Materials and Methods section.
Table 1. Binding Affinity of IgG, F(ab)2, and Fab Determined by SPR.
kon (M
−1 s−1) koff (s
−1) KD (nM)
Fab monomer 1.1 × 106 9.7 × 10−3 8.5
Fab homodimer 9.4 × 105 7.1 × 10−3 7.6
F(ab)2 monomer 1.2 × 10
6 2.9 × 10−3 2.5
F(ab)2 homodimer 1.3 × 10
6 2.9 × 10−3 2.3
IgG monomer 1.4 × 106 2.4 × 10−3 1.8
IgG homodimer 3.6 × 106 1.9 × 10−3 0.53
FGFR4 capture to measure monovalent interactions.
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0.7 and 0.8 nM, respectively, whereas the Fab binds with a binding
affinity of 11 nM (Figure 1A and Table 1). In a competition ELISA,
the IgG and F(ab)2 constructs compete for binding of FGF19 to
FGFR4 with an half-maximal inhibitory concentration (IC50) of
9 and 18 nM, respectively, whereas the Fab competes with an IC50
of 500 nM (Figure 1B).
Binding to Huh-7 cells, a hepatocellular carcinoma cell line that
expresses high levels of FGFR4 [24], was measured by FACS. The IgG
and F(ab)2 constructs have a cell binding affinity of 9 and 18 nM, respec-
tively, whereas the Fab has a binding affinity of 198 nM (Figure 1C ).
Removal of the Fc and Reduction in Size Significantly Impact
the PK Properties
PK studies were conducted by administering a single i.v. injection of
10 mg/kg of all compounds. The serum concentrations over time were
measured using an FGFR4 andCVX-2000 anti-idiotype capture binding
Figure 2. Biodistribution studies. (A) Time-dependent tumor uptake of IgG, F(ab)2, and Fab. In vivo optical imaging of near infra-red (NIR)-
conjugated constructs. Average signal intensities were quantified using regions of interest (ROIs) from the tumor sites. Data are presented
as mean fold increase from initial image capture at 30 minutes ± SEM of eight mice (***P < .001, *P < .05; IgG vs both F(ab)2 and Fab
accumulation, *P < .05 and **P < .01; F(ab)2 vs Fab accumulation by two-way ANOVA with Bonferroni post-test). Tumor and normal tissue
uptake of (B) IgG 8 hours post dose (*P < .05), (C) F(ab)2 2 hours post dose, and (D) Fab 1 hour post dose (***P < .001, **P < .01 by two-
way ANOVA with Bonferroni post-test). (E) IgG, F(ab)2, and Fab tumor uptakes and serum levels compared at the early time points of 1 hour,
2 hours, and 1 hour, respectively. At this early time point with equivalent serum levels, the targeted Fab shows maximal accumulation
levels compared to the F(ab)2 and IgG (***P < .001, **P < .01 by one-way ANOVA with Bonferroni post-test). (F) Tumor to serum levels
further demonstrate that the Fab construct accumulation is significantly higher than the IgG accumulation (*P < .05 by two-way ANOVA
with Bonferroni post-test).
566 Biodistribution of Antibody Scaffolds Muchekehu et al. Translational Oncology Vol. 6, No. 5, 2013
ELISA for total scaffold measurements (Figure 1D). The intact FGFR4
targeting CovX-body has a β half-life in mice of 60 hours, compared to
β half-lives of 4 to 6 and 1 to 3 hours for F(ab)2 and Fab, respectively.
Time-Dependent Tumor Uptake
The constructs were labeled with a near-infrared dye IRDye
800CW to allow in vivo imaging of tumor penetration and retention
in the Huh-7 hepatocellular carcinoma xenograft model. Compounds
were administered at 3 mg/kg with a single i.p. injection, and tumor
uptake was measured by image capture at the time points indicated
(Figure 2A). Maximal accumulation of the IgG was seen after 8 hours
(2.51 ± 0.47 fold increase in fluorescence relative to initial image
captured at 30 minutes, n = 8; a representative image of IgG tumor
uptake is shown in Figure W2), where accumulation was significantly
higher than the Fab and F(ab)2 constructs. The maximal accumula-
tion for the F(ab)2 construct was from 2 to 4 hours (1.63 ± 0.13 fold
increase in fluorescence, n = 8), and at these time points, the F(ab)2
accumulation was significantly higher than the Fab. Minimal accu-
mulation of the Fab was observed after 1 hour in this imaging study
(0.99 ± 0.08 fold increase in fluorescence, n = 8). In the more quan-
titative biodistribution study, where the tumors were homogenized
and accumulation was measured by ELISA, accumulation of the
Fab was observed after 1 hour (Figure 2D). This accumulation was
also confirmed by immunohistochemistry (Figure 4F ).
Tumor and Normal Tissue Uptake of Scaffolds
A biodistribution study was performed to determine the tumor
and normal tissue uptake of the FGFR4-targeted constructs and their
nontargeted controls. Animals were dosed at 30 mg/kg to quantify
the tumor and normal tissue uptake. Tumor and normal tissue were
harvested at the maximum accumulation time point derived from
the previous imaging study: 8 hours post dose for the IgG (Figure 3B),
2 hours for the F(ab)2 constructs (Figure 3C ), and 1 hour for the Fab
constructs (Figure 3D). Total scaffold accumulation was quantified
by a CVX-2000 anti-idiotype capture binding ELISA. After 8 hours,
accumulation of the nontargeted IgG is significantly higher than the
targeted IgG (5.80 ± 0.92% vs 2.3 ± 0.99% ID, respectively; P < .05,
n = 5). After 2 hours, there is a similar trend for the nontargeted
F(ab)2 vs targeted F(ab)2 accumulation; however, this is not statis-
tically significant (1.62 ± 0.58% vs 0.48 ± 0.24% ID, respectively;
P > .05, n = 5). There was no significant difference between the
targeted and nontargeted Fab after an hour (0.46 ± 0.07% vs 0.26 ±
0.06% ID, respectively; P > .05, n = 5). Both targeted and nontargeted
constructs accumulate in tumors because of the enhanced permeability
Figure 3. Increasing valency increases cell binding of bivalent constructs. (A–C) Monomer and homodimer peptide–conjugated con-
structs bind recombinant FGFR4 in a similar manner on an FGFR4 binding ELISA. Huh-7 cell binding of IgG (D) and F(ab)2 (E) homodimer-
conjugated constructs demonstrates a boost in cell binding affinity, whereas the Fab monomer and homodimer (F) have similar cell binding
affinities. (G) Anti-idiotype capture levels of anti-FGFR4monomer and homodimer compounds tomeasuremultivalent interactions. Increased
levels of FGFR4 binding is seenwith the IgG homodimer. (H) Tumor and normal tissue uptake of homodimer peptide–conjugated IgG, F(ab)2,
and Fab (*P < .05 vs monomer IgG).
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Figure 4. Increased avidity decreases penetration of scaffolds into the tumor. (A) FGFR4 staining in an adjacent section is shown. Dual
staining for blood vessels (brick red) and human IgG (brown) is shown in (B) PBS-dosed animals, (C) nontargeted IgG (8 hours), monomer
peptide–conjugated (D) IgG (8 hours), (E) F(ab)2 (2 hours), (F) Fab (1 hour) and homodimer peptide–conjugated (G) IgG (8 hours), (H) F(ab)2
(2 hours) and (I) Fab (1 hour). Arrows indicate blood vessels (red). Perivascular or diffuse construct staining from those points can be
seen. (J) Plot of average distance from randomly selected blood vessels (mean ± SEM; *P < .05, ***P < .001 by one-way ANOVA with
Bonferroni post-test).
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and retention effect; however, the differences in levels of the non-
targeted versus targeted IgG and F(ab)2 constructs may be due to inter-
nalization and “consumption” of the targeted constructs as shown in
previous studies [25].
High levels of the targeted Fab accumulated in both the lung and
spleen (4.42 ± 2.03% and 6.20 ± 1.00% ID, respectively; Figure 2D).
Both the lung and spleen normally express FGFR4 [26,27], and the
accumulation of the targeted Fab suggests that the FGFR4 binding
peptide binds both human and mouse FGFR4. It also demonstrates
the ability of the smaller Fab to rapidly accumulate in normal tissue.
Tumors were also harvested after 1 hour post dose with the IgG
for an early time point comparison with the Fab and F(ab)2 con-
structs (Figure W3). At this early time point, serum levels of the
three constructs were comparable, allowing a comparison of tumor
levels (Figure 2E ). Tumor levels as a percent of serum show that
the targeted Fab and nontargeted Fab constructs (5.81 ± 1.51%
and 3.30 ± 1.29% serum, respectively) accumulate at a higher level
than the targeted and nontargeted IgG (0.86 ± 0.27% and 0.28 ±
0.08% serum, respectively) and targeted F(ab)2 constructs (1.43 ±
0.42% serum), whereas the nontargeted F(ab)2 accumulation was
not significantly different at this early time point (3.95 ± 1.29%
serum; P > .05, n = 5; Figure 2F ).
The Role of Increased Valency in Tumor Targeting
Increasing the number of targeting peptides from two to four on
the IgG and F(ab)2 constructs and from one to two on the Fab did
not increase the apparent binding affinity to recombinant FGFR4 in
an FGFR4 capture binding ELISA (Figure 3, A–C ) or SPR (KD =
0.5, 2.3, and 7.6 nM, respectively; Table 1). It did however increase
the binding of the bivalent constructs to Huh-7 cells by 2 logs (Fig-
ure 3, D and E ) but not of the Fab (Figure 3F ).
In an SPR assay where the compounds (10 nM) were captured on
the binding surface by the anti-idiotype CVX-2000 antibody, in-
creased levels of FGFR4 binding could be measured on the tetra-
valent constructs, IgG (Figure 3G ) and F(ab)2 (data not shown)
homodimer-conjugated constructs. These bind twice the amount
of FGFR4 as the rest of the compounds, as would be expected as they
each display four peptides. Comparable levels of monomer and
homodimer constructs were captured with anti-idiotype CVX-2000
(Figure W4). This correlates with the increased cell binding we see
with these constructs in the FACS assay (Figure 3, D and E ).
Tumor and normal tissue accumulation of the homodimer-
conjugated peptides showed that increasing the valency of the IgG,
F(ab)2, and Fab did not increase the tumor levels versus their monomer
peptide–conjugated constructs (homodimer tumor accumulation of
0.82 ± 0.08%, 0.55 ± 0.12%, and 0.32 ± 0.06% ID, respectively,
n = 5; Figure 3G).
The Role of Size and Valency in Tumor Penetration
High and evenly distributed levels of FGFR4 are seen in Huh-7
tumors (Figure 4A). Adjacent FGFR4 staining of all harvested tumors
shown in Figure 4 all showed a similar high even distribution of
FGFR4. A representative section in penetration of the nontargeted
IgG construct in the tumor appears to be nonrestricted, and homog-
enous antibody staining is seen throughout the tumor (99.4 ± 10.4 μm
penetration; Figure 4C ).
Figure 5. Increased avidity leads to superior efficacy. (A) In vivo xenograft study (i.p. dosing, 30 mg/kg once weekly) and (B) in vitro cell
proliferation assay (12 nM compounds present in media for whole experiment). *P < .05, ***P< .001 by two-way ANOVA with Bonferroni
post-test. Arrows indicate dosing. (C) Phospho-Erk levels measured in tumors harvested at the end of the efficacy study; *P < .05 versus
PBS-dosed tumors by two-tailed Student’s t test. Dual staining of blood vessels and human IgG of the tumors at the end of the efficacy
study; (D) monomer peptide IgG dosed and (E) homodimer peptide IgG dosed.
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However with the monomer peptide–conjugated IgG (Figure 4D)
and F(ab)2 (Figure 4E ) constructs restricted, perivascular penetration
is seen (64 ± 3.6 and 45.5 ± 2.3 μm, respectively).
More diffuse and even penetration is seen with the Fab monomer
construct, demonstrating that the smaller scaffold is able to penetrate
further and more evenly into the tumor (117.3 ± 14.3 μm; Figure 4F ).
Increasing the affinity has been shown to decrease the penetration
into the tumor from the vessels [25], due to the hypothetical “binding
site barrier” phenomenon. Decreased tumor penetration is observed for
the homodimeric peptide versions of the IgG, F(ab)2, and Fab (32.7 ±
1.9, 25.1 ± 1.1, and 32.7 ± 1.9 μm, respectively; Figure 4, G–I ).
Increasing Valency Leads to Superior Efficacy
The binding site barrier hypothesis predicts an inverse relationship
between affinity and penetration, and this may subsequently translate
into decreased efficacy. To determine if our observation of reduced
penetration in our single dose study translates into reduced efficacy,
we compared the TGI efficacy of the tetravalent (homodimer peptide
conjugated) versus the bivalent (monomer peptide conjugated) IgG.
We observed a superior TGI with the homodimer-conjugated IgG of
50% TGI versus 22% TGI with the monomer-conjugated IgG
(975.4 ± 111.7 vs 1483 ± 266.5 mm3, respectively; P < .01, n =
10; Figure 5A).
The increased TGI is likely due to several factors. In an in vitro
proliferation assay, we observe superior inhibition of Huh-7 prolifera-
tion with the tetravalent construct compared to the monomer peptide–
conjugated IgG (cell index of 3.3 ± 0.2 vs 5.4 ± 0.2, respectively, at end
of the experiment; P < .001, n = 3; Figure 5B). Superior inhibition of
the Erk1/2 signaling pathway was seen in tumors treated with the
homodimer IgG versus monomer-conjugated IgG (0.017 ± 0.001 vs
0.030 ± 0.003, respectively; P < .05, n = 5; Figure 5C ). Increasing
the dose or concentration of a drug has been shown to overcome the
binding site barrier [7]. We show in our multi-dosed tumors that we
can overcome the “binding site barrier” observed in a single dose study
and saturated levels of the IgG constructs are observed in sections of
these tumors (Figure 5, D and E ).
The Role of Targeting and Internalization on Net Drug Levels
In our tumor and normal tissue biodistribution study (Figure 2), it
is clear that targeting is not necessary for tumor localization (targeting
is, however, necessary for efficacy). In our study, we observed higher
levels of the nontargeted IgG and F(ab)2 in the tumor (Figure 2, B
and C ). To determine whether this is due to target-mediated inter-
nalization, in vitro internalization of our constructs conjugated to
biotin was measured in Huh-7 cells as described in the Materials
and Methods section. Robust internalization of the monomer and
homodimer peptide IgG and F(ab)2 was observed at 10 and 100 nM
concentrations peaking at 60 minutes for the IgG (0.32 ± 0.01 and
2.67 ± 0.23 for the monomer and 0.62 ± 0.04 and 2.87 ± 0.002 for
the homodimer, respectively; Figure 6A) and 15 minutes for the F(ab)2
(0.14 ± 0.01 and 1.31 ± 0.05 for the monomer and 0.28 ± 0.004 and
2.61 ± 0.11 for the homodimer, respectively; Figure 6B). Negligible
internalization was seen with the Fab constructs at 10 nM, whereas
a significant increase in internalization of the homodimer-conjugated
Fab versus the monomer Fab was seen at 100 nM (0.32 ± 0.001 vs
0.05 ± 0.003 respectively; Figure 6C ).
Internalization and subsequent degradation of the IgG and F(ab)2
constructs in vivo may contribute to the lower levels of the targeted
constructs measured.
Discussion
The Role of Molecular Weight
Low accumulation levels of the F(ab)2 and Fab constructs are
achieved in a single dose study (Figure 2). At the early time points
of 1 to 2 hours though, we can see that more of the Fab and F(ab)2
constructs get into the tumor than the IgG (Figure 2, E and F ).
Further, the Fab appears to rapidly and evenly distribute in the
tumor (Figure 4F ), demonstrating some benefit of reduced size. How-
ever, the Fab also ultimately produced lower maximum drug delivery
than the IgG and a less favorable tumor/normal tissue ratio, reflecting
less restricted diffusion into normal tissues as well (Figure 2D).
Although there have been some studies demonstrating improved
tumor uptake and penetration with F(ab)2 antibody scaffolds
[28,29], the F(ab)2 construct used in this study overall has the least
favorable profile in terms of low accumulation (Figure 2C ) and
minimal tumor penetration (Figure 4E). The limited tumor penetra-
tion of the F(ab)2 fragment in this current study may be due to inter-
nalization of our targeted construct (Figure 6B). Internalization and
consumption of constructs may lead to decreased tumor penetration
[25] and may contribute to the differences in the levels of tumor
penetration seen in this current study and previously published work.
The F(ab)2 construct also resides in what is termed a “death valley” of
Figure 6. Multivalent binding is required for internalization. Internalization assays were conducted by incubating Huh-7 cells with
biotinylated constructs at concentrations indicated at 37°C. Maximal internalization was seen at (A) 60 minutes for IgG constructs
and 15 minutes for the (B) F(ab)2 and (C) Fab constructs. The average ± SD is shown (*P < .05, **P < .01, ***P < .001 by two-way
ANOVA with Bonferroni posttest).
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maximum tumor uptake versus size [30], too large to rapidly extravasate
into the tumor tissue and too small to escape renal clearance.
Targeting Is Not Necessary for Tumor Localization
Both targeting and nontargeting versions of our constructs accu-
mulated in the tumor (Figure 2). The accumulation of nontargeting
constructs in tumors has been demonstrated in multiple studies,
including the similar accumulation of epidermal growth factor recep-
tor (EGFR)–targeted and nontargeted liposomes in EGFR-expressing
tumors [31] as well as HER2-targeted and nontargeted liposomes in
HER2-expressing models [32]. This accumulation is hypothesized to
be due to the enhanced permeability effect, caused by leaky tumor
vasculature [33,34], and the absence of a functional lymphatic system,
leading to retention of constructs [6,30].
The Role of Avidity and Internalization
While the relationship between affinity and target inhibition is
well established, the relationship between valency on cell-based target
binding and inhibition is less appreciated, although potentially more
robust in the context of cell-based assays. This was shown in a recent
study in which EGFR-binding Fab and IgG demonstrated log-fold or
better binding and target inhibition with bivalency [35].
Increasing the cell binding functional affinity (avidity) of all our
constructs using a homodimer peptide does not increase the quan-
titative tumor levels and limits tumor penetration (Figures 3G and
4). These findings correlate with the work on HER2 binding anti-
bodies [25], where the investigators demonstrated a decrease in quan-
titative tumor levels and penetration with increasing affinity and
internalization. The lower quantitative levels of the targeted versus
nontargeting controls, as well as the monomeric versus homodimeric
constructs, are likely due to internalization and degradation of the
targeted constructs.
An increase in cell binding was not seen in the Fab construct
going from a monomer peptide to a homodimer peptide (Figure 3F ).
Although not explored in this study, the space between two peptides
on a linker may not provide sufficient benefit to translate into an
increase in the cell binding affinity. Bivalent binding has, however,
been shown to be important for internalization [36], and although
an increase in cell binding affinity is not seen, in our in vitro internal-
ization study, the monovalent Fab did not internalize, whereas the
homodimer-conjugated Fab did (Figure 6C ).
The internalization of the homodimer-conjugated Fab may also
contribute to the decreased tumor penetration seen with the Fab
homodimer peptide–conjugated construct (Figure 4I ). Increasing
the valency of the IgG and F(ab)2 increased the total internalization
at 10 nM for the IgG and significantly at 100 nM for the F(ab)2.
Increasing the valency particularly on our bivalent constructs may
lead to cross-linking of more receptors and more robust internaliza-
tion as has been demonstrated by glycosylphosphatidylinositol (GPI)-
anchored folate receptors [37].
Contrary to predictions that increased affinity and decreased
penetration seen in single dose studies may translate into poor effi-
cacy, we demonstrate that increasing the avidity of our IgG translates
into superior efficacy (Figure 5A). This is likely due to several factors
such as more effective inhibition of proliferation and inhibition of
the Erk1/2 signaling pathway that drives FGF19–FGFR4-mediated
proliferation [38] (Figure 5, B and C ). In addition, we demonstrate
that one can dose through the “binding site barrier” (Figure 5D) [7].
Improved retention with increased avidity has been demonstrated
using diabodies to investigate the role of valency on tumor uptake
[13,17]. Although we do not see higher quantitative levels with in-
creased valency (most likely due to internalization and consumption),
our study demonstrates that increasing the valency can be an efficient
way to increase the efficacy of targeting molecules.
In conclusion, the most promising candidate for FGFR4 antibody–
targeted therapies would be the homodimer peptide–conjugated IgG.
With an optimal PK profile and MW, this construct demonstrated
effective inhibition of FGFR4-mediated proliferation pathways,
which directly translated into superior efficacy. In general, increasing
the valence of a receptor-targeted therapy is an effective way to
increase efficacy.
Acknowledgments
We thank M. Ong for his technical expertise with conjugation,
E. Corner and J. Hoye for help with scaffold generation, and
J. Churchman for help running the Biacore experiment.
References
[1] Tunggal JK, Cowan DS, Shaikh H, and Tannock IF (1999). Penetration of
anticancer drugs through solid tissue: a factor that limits the effectiveness of
chemotherapy for solid tumors. Clin Cancer Res 5, 1583–1586.
[2] Sedlacek HH, Seemann G, Hoffmann D, Czech J, Lorenz P, Kolar C, and
Bosslet K (1992). Antibodies as carriers of cytotoxicity. In Contributions to Oncology.
Vol 43. H Huber and W Queiber (Eds). Karger, Basel, Switzerland, pp. 74–75.
[3] Ackerman ME, Pawlowski D, and Wittrup KD (2008). Effect of antigen turn-
over rate and expression level on antibody penetration into tumor spheroids.
Mol Cancer Ther 7, 2233–2240.
[4] Chaplin DJ, Olive PL, and Durand RE (1987). Intermittent blood flow in a
murine tumor: radiobiological effects. Cancer Res 47, 597–601.
[5] Heldin CH, Rubin K, Pietras K, and Ostman A (2004). High interstitial fluid
pressure—an obstacle in cancer therapy. Nat Rev Cancer 4, 806–813.
[6] Jain RK (1994). Barriers to drug delivery in solid tumors. Sci Am 271, 58–65.
[7] Saga T, Neumann RD, Heya T, Sato J, Kinuya S, Le N, Paik CH, andWeinstein
JN (1995). Targeting cancer micrometastases with monoclonal antibodies: a
binding-site barrier. Proc Natl Acad Sci USA 92, 8999–9003.
[8] Fujimori K, Covell DG, Fletcher JE, and Weinstein JN (1989). Modeling
analysis of the global and microscopic distribution of immunoglobulin G, F(ab′)2,
and Fab in tumors. Cancer Res 49, 5656–5663.
[9] Teillaud JL (2012). From whole monoclonal antibodies to single domain anti-
bodies: think small. Methods Mol Biol 911, 3–13.
[10] Kim SJ, Park Y, and Hong HJ (2005). Antibody engineering for the develop-
ment of therapeutic antibodies. Mol Cells 20, 17–29.
[11] Minchinton AI and Tannock IF (2006). Drug penetration in solid tumours.
Nat Rev Cancer 6, 583–592.
[12] Thurber GM, Zajic SC, and Wittrup KD (2007). Theoretic criteria for anti-
body penetration into solid tumors and micrometastases. J Nucl Med 48,
995–999.
[13] Adams GP, Schier R, McCall AM, Crawford RS, Wolf EJ, Weiner LM, and
Marks JD (1998). Prolonged in vivo tumour retention of a human diabody
targeting the extracellular domain of human HER2/neu. Br J Cancer 77,
1405–1412.
[14] Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK,
Marks JD, and Weiner LM (2001). High affinity restricts the localization
and tumor penetration of single-chain fv antibody molecules. Cancer Res 61,
4750–4755.
[15] Nelson AL (2010). Antibody fragments: hope and hype. MAbs 2, 77–83.
[16] Yokota T, Milenic DE, Whitlow M, and Schlom J (1992). Rapid tumor pene-
tration of a single-chain Fv and comparison with other immunoglobulin forms.
Cancer Res 52, 3402–3408.
[17] Nielsen UB, Adams GP, Weiner LM, and Marks JD (2000). Targeting of
bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent
of the intrinsic antibody affinity. Cancer Res 60, 6434–6440.
Translational Oncology Vol. 6, No. 5, 2013 Biodistribution of Antibody Scaffolds Muchekehu et al. 571
[18] Zahnd C, Kawe M, Stumpp MT, de Pasquale C, Tamaskovic R, Nagy-
Davidescu G, Dreier B, Schibli R, Binz HK, Waibel R, et al. (2010). Efficient
tumor targeting with high-affinity designed ankyrin repeat proteins: effects of
affinity and molecular size. Cancer Res 70, 1595–1605.
[19] Adams GP, Tai MS, McCartney JE, Marks JD, Stafford WF III, Houston
LL, Huston JS, and Weiner LM (2006). Avidity-mediated enhancement
of in vivo tumor targeting by single-chain Fv dimers. Clin Cancer Res 12,
1599–1605.
[20] Huang H, Lai JY, Do J, Liu D, Li L, Del Rosario J, Doppalapudi VR,
Pirie-Shepherd S, Levin N, Bradshaw C, et al. (2011). Specifically targeting
angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration,
and tumor growth. Clin Cancer Res 17, 1001–1011.
[21] Blumenthal RD, Fand I, Sharkey RM, Boerman OC, Kashi R, and Goldenberg
DM (1991). The effect of antibody protein dose on the uniformity of tumor
distribution of radioantibodies: an autoradiographic study. Cancer Immunol
Immunother 33, 351–358.
[22] Rader C, Turner JM, Heine A, Shabat D, Sinha SC, Wilson IA, Lerner RA, and
Barbas CF (2003). A humanized aldolase antibody for selective chemotherapy
and adaptor immunotherapy. J Mol Biol 332, 889–899.
[23] Doppalapudi VR, Huang J, Liu D, Jin P, Liu B, Li L, Desharnais J, Hagen C,
Levin NJ, Shields MJ, et al. (2010). Chemical generation of bispecific anti-
bodies. Proc Natl Acad Sci USA 107, 22611–22616.
[24] Ho HK, Pok S, Streit S, Ruhe JE, Hart S, Lim KS, Loo HL, Aung MO, Lim
SG, and Ullrich A (2009). Fibroblast growth factor receptor 4 regulates pro-
liferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular
carcinoma progression and represents a potential target for therapeutic interven-
tion. J Hepatol 50, 118–127.
[25] Rudnick SI, Lou J, Shaller CC, Tang Y, Klein-Szanto AJ, Weiner LM, Marks
JD, and Adams GP (2011). Influence of affinity and antigen internalization on
the uptake and penetration of anti-HER2 antibodies in solid tumors. Cancer
Res 71, 2250–2259.
[26] Lin BC, Wang M, Blackmore C, and Desnoyers LR (2007). Liver-specific
activities of FGF19 require Klotho beta. J Biol Chem 282, 27277–27284.
[27] Yu SJ, Zheng L, Ladanyi M, Asa SL, and Ezzat S (2004). Sp1-mediated tran-
scriptional control of fibroblast growth factor receptor 4 in sarcomas of skeletal
muscle lineage. Clin Cancer Res 10, 6750–6758.
[28] Fleuren ED, Versleijen-Jonkers YM, Heskamp S, Roeffen MH, Bouwman WH,
Molkenboer-Kuenen JD, van Laarhoven HW, Oyen WJ, Boerman OC, and
van der Graaf WT (2013). The strength of small: improved targeting of
insulin-like growth factor-1 receptor (IGF-1R) with F(ab′)-R1507 fragments
in Ewing sarcomas. Eur J Cancer, E-pub ahead of print.
[29] Sandström K, Haylock AK, Spiegelberg D, Qvarnström F, Wester K, and
Nestor M (2012). A novel CD44v6 targeting antibody fragment with improved
tumor-to-blood ratio. Int J Oncol 40, 1525–1532.
[30] Wittrup KD, Thurber GM, Schmidt MM, and Rhoden JJ (2012). Practical
theoretic guidance for the design of tumor-targeting agents. Methods Enzymol
503, 255–268.
[31] Mamot C, Drummond DC, Noble CO, Kallab V, Guo Z, Hong K, Kirpotin
DB, and Park JW (2005). Epidermal growth factor receptor–targeted immuno-
liposomes significantly enhance the efficacy of multiple anticancer drugs in vivo.
Cancer Res 65, 11631–11638.
[32] Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB,
Marks JD, Benz CC, and Park JW (2006). Antibody targeting of long-circulating
lipidic nanoparticles does not increase tumor localization but does increase inter-
nalization in animal models. Cancer Res 66, 6732–6740.
[33] Sands H, Jones PL, Shah SA, Palme D, Vessella RL, and Gallagher BM (1988).
Correlation of vascular permeability and blood flow with monoclonal antibody
uptake by human Clouser and renal cell xenografts. Cancer Res 48, 188–193.
[34] Dvorak HF, Nagy JA, Dvorak JT, and Dvorak AM (1988). Identification and
characterization of the blood vessels of solid tumors that are leaky to circulating
macromolecules. Am J Pathol 133, 95–109.
[35] Zhou Y, Goenaga AL, Harms BD, Zou H, Lou J, Conrad F, Adams GP,
Schoeberl B, Nielsen UB, and Marks JD (2012). Impact of intrinsic affinity
on functional binding and biological activity of EGFR antibodies. Mol Cancer
Ther 11, 1467–1476.
[36] Kyriakos RJ, Shih LB, Ong GL, Patel K, Goldenberg DM, and Mattes MJ
(1992). The fate of antibodies bound to the surface of tumor cells in vitro.
Cancer Res 52, 835–842.
[37] Mayor S, Rothberg KG, and Maxfield FR (1994). Sequestration of GPI-
anchored proteins in caveolae triggered by cross-linking. Science 264, 1948–1951.
[38] Lin BC and Desnoyers LR (2012). FGF19 and cancer. Adv Exp Med Biol
728, 183–194.
572 Biodistribution of Antibody Scaffolds Muchekehu et al. Translational Oncology Vol. 6, No. 5, 2013
Figure W1. Purified fractions of CovX-body, F(ab)2, and Fab run on
a Bioanalyzer protein electrophoresis chip (Agilent Technologies).
Figure W2. A representative image of IgG tumor uptake 8 hours
after dosing. Clear uptake into the tumor (T) is seen.
Figure W4. Anti-idiotype capture levels of anti-FGFR4 monomer
and homodimer compounds to measure multivalent interactions.
Comparable levels of monomer and homodimer constructs were
captured with anti-idiotype CVX-2000.
Figure W3. Tumor and normal tissue uptakeof IgG1hour post dose.
